Guangdong Nanguo Pharmaceutical Co. Ltd.

To investigate whether there are differences in the extent and rate of absorption of the test preparation estazolam tablets (Guangdong Nanguo Pharmaceutical Co., Ltd., specification: 1 mg) and the reference preparation estazolam tablets (trade name: EURODIN®; Teva Takeda Yakuhin Ltd., specification: 1 mg) after a single oral administration on an empty stomach or after a meal in healthy subjects, to evaluate the bioequivalence of the test preparation and the reference preparation when administered on an empty stomach or after a meal, and to observe the safety of the test preparation and the reference preparation in healthy subjects.

This study investigates whether there are differences in the absorption rate and extent between the test formulation alprazolam tablets (Guangdong Nanguo Pharmaceutical Co., Ltd., specification: 0.4 mg) and the reference formulation alprazolam tablets (trade name: Solanax®; Viatris Pharmaceutical Co., Ltd., specification: 0.4 mg) administered orally to healthy study participants on an empty stomach. It also evaluates the bioequivalence of the test and reference formulations when administered on an empty stomach and observes their safety in healthy study participants.

This study investigates whether there are differences in the absorption rate and extent between a single oral dose of the test formulation alprazolam tablets (Guangdong Nanguo Pharmaceutical Co., Ltd., specification: 0.4 mg) and the reference formulation alprazolam tablets (trade name: Solanax®; Viatris Pharmaceutical Co., Ltd., specification: 0.4 mg) after a meal in healthy study participants. It also evaluates the bioequivalence of the test and reference formulations when administered after a meal and observes their safety in healthy study participants.